Published in Exp Neurol on January 18, 2012
Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. J Cell Biol (2014) 2.95
Purkinje cell axonal anatomy: quantifying morphometric changes in essential tremor versus control brains. Brain (2013) 1.62
Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism. Neuron (2016) 1.04
Transcription, epigenetics and ameliorative strategies in Huntington's Disease: a genome-wide perspective. Mol Neurobiol (2014) 0.96
Diverse cellular and molecular modes of axon degeneration. Trends Cell Biol (2014) 0.92
Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol (2015) 0.92
Methamphetamine causes degeneration of dopamine cell bodies and terminals of the nigrostriatal pathway evidenced by silver staining. Neuropsychopharmacology (2013) 0.87
Neuroimaging of Parkinson's disease: Expanding views. Neurosci Biobehav Rev (2015) 0.87
Naringin: a protector of the nigrostriatal dopaminergic projection. Exp Neurobiol (2014) 0.86
Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity. Dis Model Mech (2014) 0.86
Effects of naringin, a flavanone glycoside in grapefruits and citrus fruits, on the nigrostriatal dopaminergic projection in the adult brain. Neural Regen Res (2014) 0.85
The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons. Mol Neurodegener (2014) 0.85
CRMP4 and CRMP2 Interact to Coordinate Cytoskeleton Dynamics, Regulating Growth Cone Development and Axon Elongation. Neural Plast (2015) 0.85
Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. Cell Death Dis (2015) 0.84
AxonQuant: A Microfluidic Chamber Culture-Coupled Algorithm That Allows High-Throughput Quantification of Axonal Damage. Neurosignals (2014) 0.84
Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. Neurobiol Dis (2014) 0.83
Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease. Lab Invest (2014) 0.81
Lmx1a and Lmx1b regulate mitochondrial functions and survival of adult midbrain dopaminergic neurons. Proc Natl Acad Sci U S A (2016) 0.80
Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Int J Mol Sci (2016) 0.80
Presynaptic effects of levodopa and their possible role in dyskinesia. Mov Disord (2014) 0.80
Alpha-synuclein mutations impair axonal regeneration in models of Parkinson's disease. Front Aging Neurosci (2014) 0.78
Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease. Neurobiol Dis (2015) 0.78
Changes in neuronal dopamine homeostasis following 1-methyl-4-phenylpyridinium (MPP+) exposure. J Biol Chem (2015) 0.78
Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism. Br J Pharmacol (2015) 0.78
Magnetic resonance imaging (MRI) to study striatal iron accumulation in a rat model of Parkinson's disease. PLoS One (2014) 0.78
Mammalian target of rapamycin complex 1 as an inducer of neurotrophic factors in dopaminergic neurons. Neural Regen Res (2014) 0.77
In vivo measures of nigrostriatal neuronal response to unilateral MPTP treatment. Brain Res (2014) 0.77
IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases. Exp Brain Res (2016) 0.77
Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats. Autophagy (2016) 0.77
Upregulation of Glutaredoxin-1 Activates Microglia and Promotes Neurodegeneration: Implications for Parkinson's Disease. Antioxid Redox Signal (2016) 0.76
TMEM184b Promotes Axon Degeneration and Neuromuscular Junction Maintenance. J Neurosci (2016) 0.75
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. Front Neurosci (2016) 0.75
Identification of Multiple QTLs Linked to Neuropathology in the Engrailed-1 Heterozygous Mouse Model of Parkinson's Disease. Sci Rep (2016) 0.75
Linking Inflammation and Parkinson Disease: Hypochlorous Acid Generates Parkinsonian Poisons. Toxicol Sci (2016) 0.75
Dissecting the role of Engrailed in adult dopaminergic neurons - Insights into Parkinson disease pathogenesis. FEBS Lett (2015) 0.75
Early Degeneration of Both Dopaminergic and Serotonergic Axons - A Common Mechanism in Parkinson's Disease. Front Cell Neurosci (2016) 0.75
The effects of gestational and chronic atrazine exposure on motor behaviors and striatal dopamine in male Sprague-Dawley rats. Toxicol Appl Pharmacol (2015) 0.75
Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. Nat Commun (2017) 0.75
Imaging and Quantitative Analysis of the Interstitial Space in the Caudate Nucleus in a Rotenone-Induced Rat Model of Parkinson's Disease Using Tracer-based MRI. Aging Dis (2017) 0.75
In vivo characterization of the connectivity and subcomponents of the human globus pallidus. Neuroimage (2015) 0.75
Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson's Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory Mechanisms. Front Neuroanat (2017) 0.75
Neuroprotective Transcription Factors in Animal Models of Parkinson Disease. Neural Plast (2015) 0.75
Roles of Rheb(S16H) in substantia nigra pars compacta dopaminergic neurons in vivo. Biomed Rep (2014) 0.75
Selenoprotein T Exerts an Essential Oxidoreductase Activity That Protects Dopaminergic Neurons in Mouse Models of Parkinson's Disease. Antioxid Redox Signal (2016) 0.75
The SAC1 domain in synaptojanin is required for autophagosome maturation at presynaptic terminals. EMBO J (2017) 0.75
Involvement of Peripheral Nerves in the Transgenic PLP-α-Syn Model of Multiple System Atrophy: Extending the Phenotype. PLoS One (2015) 0.75
Manganese-Enhanced Magnetic Resonance Imaging for Detection of Vasoactive Intestinal Peptide Receptor 2 Agonist Therapy in a Model of Parkinson's Disease. Neurotherapeutics (2016) 0.75
Changes in functional organization and white matter integrity in the connectome in Parkinson's disease. Neuroimage Clin (2016) 0.75
Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson's disease. Sci Rep (2017) 0.75
Respiratory chain inhibition: one more feature to propose MPTP intoxication as a Leigh syndrome model. J Bioenerg Biomembr (2016) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2002) 9.90
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med (2001) 9.51
mTOR signaling at a glance. J Cell Sci (2009) 8.66
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Immunogenicity of induced pluripotent stem cells. Nature (2011) 7.31
Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science (2008) 6.86
Parkinson's disease. Lancet (2009) 6.60
mTOR regulation of autophagy. FEBS Lett (2010) 6.59
APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature (2009) 6.17
Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med (1988) 4.98
The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron (1995) 4.78
[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr (1960) 4.77
Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron (2011) 4.74
The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron (2006) 4.51
A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans (2009) 4.37
Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci (1988) 4.36
Axonal self-destruction and neurodegeneration. Science (2002) 4.30
PTEN deletion enhances the regenerative ability of adult corticospinal neurons. Nat Neurosci (2010) 4.28
Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci (2001) 4.10
LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J (2007) 3.89
Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem (2008) 3.86
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci (2003) 3.30
Absence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. Eur J Neurosci (1989) 3.24
Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci (2009) 3.24
Wallerian degeneration, wld(s), and nmnat. Annu Rev Neurosci (2010) 3.22
Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci (2007) 2.96
Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem (2010) 2.90
Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro (2009) 2.85
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol (2002) 2.70
A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol (2008) 2.44
Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci (2009) 2.44
Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci (2002) 2.40
Parkinson's disease: genetics and pathogenesis. Annu Rev Pathol (2011) 2.39
Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J Neurosci (2009) 2.36
Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J Neurosci (2002) 2.31
Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci U S A (1999) 2.30
Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. J Neurosci (2009) 2.15
Lewy bodies. Proc Natl Acad Sci U S A (2006) 2.15
Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain (2007) 2.10
The interplay between mitochondrial dynamics and mitophagy. Antioxid Redox Signal (2011) 2.05
Evidence that Wallerian degeneration and localized axon degeneration induced by local neurotrophin deprivation do not involve caspases. J Neurosci (2000) 2.04
Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol (1988) 2.01
Wld S requires Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian degeneration. J Cell Biol (2009) 1.98
alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol (2004) 1.97
Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol (2010) 1.88
Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. J Neurosci (2009) 1.78
The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry (1991) 1.68
Biochemical aspects of Parkinson's disease. Neurology (1998) 1.67
Axonal degeneration is mediated by the mitochondrial permeability transition pore. J Neurosci (2011) 1.67
In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol (2000) 1.65
Suppression of radixin and moesin alters growth cone morphology, motility, and process formation in primary cultured neurons. J Cell Biol (1998) 1.63
Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci U S A (2008) 1.61
Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology (1987) 1.61
The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem (2000) 1.60
Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J Neurosci (2006) 1.57
Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Curr Biol (2004) 1.55
Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm (1976) 1.54
Nmnat delays axonal degeneration caused by mitochondrial and oxidative stress. J Neurosci (2008) 1.54
Wld S protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice. J Cell Biol (2009) 1.53
Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol (2005) 1.52
A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies. J Neurol Sci (2001) 1.51
1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc Natl Acad Sci U S A (2007) 1.51
Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci U S A (2006) 1.51
Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology (2009) 1.48
Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol (2006) 1.48
Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol (2008) 1.47
Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol (1997) 1.47
Induction of autophagy in neurite degeneration of mouse superior cervical ganglion neurons. Eur J Neurosci (2007) 1.45
Hyperactivation of mammalian target of rapamycin (mTOR) signaling by a gain-of-function mutant of the Rheb GTPase. J Biol Chem (2006) 1.42
Parkinson's disease. Lancet (1990) 1.39
Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol (2002) 1.39
SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain (2010) 1.38
Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol (2011) 1.38
Non-apoptotic neurite degeneration in apoptotic neuronal death: pivotal role of mitochondrial function in neurites. Neuroscience (2003) 1.34
Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS One (2008) 1.32
The parkinsonian mimetic, MPP+, specifically impairs mitochondrial transport in dopamine axons. J Neurosci (2011) 1.31
Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J Neurosci (2011) 1.28
Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson's disease model. J Cell Biol (2011) 1.28
Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Exp Neurol (2006) 1.27
Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience (1991) 1.23
Medial forebrain bundle axotomy during development induces apoptosis in dopamine neurons of the substantia nigra and activation of caspases in their degenerating axons. J Comp Neurol (2002) 1.23
Wld(S), Nmnats and axon degeneration--progress in the past two decades. Protein Cell (2010) 1.21
Dysautonomia in Parkinsonism: a clinicopathological study. J Neurol Neurosurg Psychiatry (1976) 1.21
Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol (2011) 1.19
Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Sci (2006) 1.17